Dopaminergic mechanisms of inference for language: a pharmaco-fMRI study

Published: 21-07-2022 Last updated: 28-09-2024

The primary objective of this study is to investigate whether increases in brain dopamine enhance novel meaning inference in language processing, and what cognitive and neural mechanisms underlie this. We will test the hypothesis that dopamine...

Ethical review Approved WMO

Status Recruitment stopped

Health condition type Other condition

Study type Observational invasive

Summary

ID

NL-OMON53778

Source

ToetsingOnline

Brief title

Dopamine's role in linguistic inference

Condition

Other condition

Synonym

brain

Health condition

Neuroscience research (basic science)

Research involving

Human

Sponsors and support

Primary sponsor: Radboud Universiteit Nijmegen

Source(s) of monetary or material Support: NWO (Nederlandse Organisatie voor

Wetenschappelijk Onderzoek);Language in Interaction

Intervention

Keyword: Dopamine, fMRI, Inference, Language

Outcome measures

Primary outcome

BOLD signal measured with fMRI; behavioural performance on cognitive tasks.

Secondary outcome

Subjective measurements (e.g., self-report questionnaires, visual analogue scales)

Study description

Background summary

Humans are flexible and efficient at inferring meaning during language processing. Similar capacity has also been observed in making novel decisions drawing from past experience, for example in spatial relations.

Dopamine is the key neural candidate posited to play a crucial role in drawing inferences in non-linguistic domains. Dopamine is a catecholamine neurotransmitter that is known to play a central role in flexible and self-directed thought and action: our abilities to think about and make plans based on stimuli that are not physically present (working memory), to learn from new information and stimulus-response associations (reinforcement learning), and to make choices based on prior and current environment (incentive motivation), all critically rely on dopamine. Particularly, dopamine stimulation leads to flexible and adaptive behaviour, making it a likely component for inferential reasoning.

Besides its role in flexible behaviour, dopamine has also been linked to language processing: previous research has shown the importance of dopamine in amplifying the salience of linguistic information (e.g. enhancing semantic

processing). This is consistent with the idea that dopamine increases signal-to-noise ratio between specific signals and background noise.

This study addresses fundamental questions about the neural mechanisms that are central to our capacity to infer meanings flexibly and efficiently during language processing, broadening the role of dopamine from action and spatial planning to linguistic relations.

Study objective

The primary objective of this study is to investigate whether increases in brain dopamine enhance novel meaning inference in language processing, and what cognitive and neural mechanisms underlie this. We will test the hypothesis that dopamine promotes the building of novel word meaning representations and increases the signal to noise ratio of existing word meaning representations in the hippocampus and prefrontal cortex.

Study design

A double-blind placebo-controlled between-subject design will be employed: Healthy participants are tested once, either on placebo or on a low oral dose (150mg) of the dopaminergic precursor, levodopa, in order to increase brain dopamine. Similar pharmacological designs, albeit with other dopaminergic pharmacological challenges, are commonly used in our lab. The proposed dose of levodopa has been widely used without side effects in other studies with comparable study populations.

Study burden and risks

Participants will attend two study sessions: a screening session and a pharmaco-fMRI session (levodopa or placebo). On the pharmaco-fMRI session, participants will complete questionnaires, structural and functional MRI scans, as well as a battery of tasks both in (during the fMRI scans) and outside the scanner. On the day preceding each pharmaco-fMRI session, participants will have to adhere to some simple restrictions with respect to medication, alcohol and drug intake. On the pharmaco-fMRI day, subjects will have to refrain from smoking and stimulant-containing drinks. Levodopa can be administered safely without any relevant risk of serious adverse events and has been approved for clinical use in the Netherlands.

Contacts

Public

Radboud Universiteit Nijmegen

3 - Dopaminergic mechanisms of inference for language: a pharmaco-fMRI study 24-06-2025

Kapittelweg 29 Nijmegen 6525 EN NL

Scientific

Radboud Universiteit Nijmegen

Kapittelweg 29 Nijmegen 6525 EN NL

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age

Adults (18-64 years)

Inclusion criteria

Healthy volunteers between 18 and 45 years of age; Dutch native speaker; Predominant right-handedness;

Exclusion criteria

Neuropsychiatric disorders; history of drug abuse; metal objects in or around the body (see section 4.3 in the Research Protocol C1 for full list of exclusion criteria).

Study design

Design

Study type: Observational invasive

Intervention model: Parallel

Allocation: Randomized controlled trial

Masking: Double blinded (masking used)

Control: Placebo

Primary purpose: Other

Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 24-11-2022

Enrollment: 90

Type: Actual

Ethics review

Approved WMO

Date: 21-07-2022

Application type: First submission

Review commission: CMO regio Arnhem-Nijmegen (Nijmegen)

Approved WMO

Date: 22-11-2022

Application type: Amendment

Review commission: CMO regio Arnhem-Nijmegen (Nijmegen)

Approved WMO

Date: 01-05-2023

Application type: Amendment

Review commission: CMO regio Arnhem-Nijmegen (Nijmegen)

Approved WMO

Date: 31-07-2023

Application type: Amendment

Review commission: CMO regio Arnhem-Nijmegen (Nijmegen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register ID

CCMO NL80626.091.22